Drug Discovery Informatics Market Report 2025

The drug discovery informatics market size has grown rapidly in recent years. It will grow from $3.69 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to genomics and proteomics advancements, increasing complexity of drug targets, advancements in structural biology, rise in outsourcing, pharmacogenomics integration, drug repurposing strategies.

The drug discovery informatics market size is expected to see rapid growth in the next few years. It will grow to $6.98 billion in 2029 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to expansion of precision medicine, drug-drug interaction prediction, patient-derived data analysis, biosimilars development, growing number of drug candidates. Major trends in the forecast period include ai and machine learning integration, digital twins in drug development, collaboration platforms, blockchain for data security, advancements in imaging technologies, cloud-based informatics platforms.

The increasing prevalence of chronic diseases is anticipated to drive the expansion of the drug discovery informatics market. Chronic illnesses persist for extended periods, requiring ongoing medical attention and often hindering daily activities. Drug discovery informatics systems play a pivotal role in advancing chronic disease care. These systems enable researchers to delve into complex molecular changes underlying disease progression and drug response, resulting in comprehensive models of the hierarchical system across healthy, diseased, and treated states. For instance, a report by the World Health Organization in 2022 highlighted that non-communicable diseases (NCDs) are projected to cause 41 million deaths, accounting for 74% of global fatalities. These diseases claim 17 million lives annually before the age of 70, with low- and middle-income countries contributing to 86% of premature deaths. Cardiovascular diseases rank highest in annual fatalities (17.9 million), followed by cancer (9.3 million), chronic respiratory disorders (4.1 million), and diabetes (2 million, including diabetes-induced kidney disease). Hence, the growing prevalence of chronic diseases drives the growth of the drug discovery informatics market.

The growing investment in research and development (R&D) activities is anticipated to drive the growth of the drug discovery informatics market in the future. R&D activities refer to systematic and creative efforts undertaken by companies, organizations, or individuals to discover, develop, and improve products, processes, or services. Investments in R&D within drug discovery informatics lead to a more efficient, innovative, and cost-effective drug development process, enhance data analysis and integration, improve target identification and validation, and facilitate predictive modeling and simulation of drug interactions and biological processes. For example, in February 2024, the Office for National Statistics, a UK-based government department, reported that UK businesses spent £49.9 billion on research and development (R&D) in 2022, marking an increase of $3.89 billion (£3 billion) (6.4%) compared to 2021. This data represents the first reporting period based on the new sample design and results methodology. The pharmaceuticals product group was the largest contributor to total business R&D expenditure, accounting for $11.69 billion (£9 billion), or 17.9% of the total R&D conducted by UK companies. Therefore, the rising investment in research and development activities is propelling the growth of the drug discovery informatics market.

Technological advancements have become a significant trend gaining traction in the drug discovery informatics market. Leading companies in this field are concentrating on developing innovative solutions to maintain and enhance their market position. For instance, in March 2023, Illumina Inc., a US-based biotechnology firm, introduced Connected Insights, a new cloud-based software designed for tertiary analysis of clinical next-generation sequencing (NGS) data. Connected Insights aims to streamline the interpretation and reporting processes across various assay types, allowing laboratories to expand the use of NGS and reduce the turnaround time for clinical reporting through the integration of third-party knowledge bases. Ultimately, it is intended to support a wide array of applications, including whole-genome sequencing (WGS) for rare diseases in the near future. Illumina Connected Software serves as a comprehensive software ecosystem that standardizes analytical tools and connects data throughout the genomics workflow. By integrating with Illumina sequencers and providing access to DRAGEN secondary analysis, Illumina Connected Software offers an efficient, accurate, and flexible analytical environment, tailored to scale according to each customer's workflow.

Leading companies within the drug discovery informatics market are directing their efforts toward innovative offerings, such as AI-powered solutions in life sciences, to drive market revenues. AI-driven solutions in life sciences are instrumental in advancing precision medicine and drug discovery, potentially revolutionizing the creation of new therapies and personalized treatment plans. These advancements aim to enhance the speed, accuracy, and efficiency of research and development processes within the life sciences industry. For instance, in May 2023, Google Cloud Platform, a US-based technology company, introduced AI-powered life sciences solutions such as the Target and Lead Identification Suite and the Multiomics Suite. These solutions aim to transform life sciences enterprises by expediting drug research and hastening the introduction of novel treatments. Utilizing high-performance computing, generative AI, and sophisticated computational tools, these methods predict protein structures, delineate the function of amino acids, and analyze genetic data. The Multiomics Suite contributes to precision medicine tools, while the Target and Lead Identification Suite aids in more effective in silico drug design.

In November 2022, Norstella, a US-based provider of pharmaceutical consultancy services and solutions, merged with Citeline. This strategic merger positions Norstella to prioritize rapid innovation, guiding life sciences companies throughout the entire drug development process, thereby accelerating the availability of medications for patients. Citeline, based in the US, specializes in providing pharmaceutical intelligence for research and development, offering insights into various drug trials. This merger signifies a significant step in facilitating swift and efficient drug development, ultimately benefiting patients by expediting the availability of essential medications.

Major companies operating in the drug discovery informatics market include Accenture Plc., Certara Inc., Charles River Laboratories Inc., Infosys Ltd., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products Inc., Jubilant Biosys Ltd., Selvita S.A., PerkinElmer Inc., International Business Machines Corporation, Boehringer Ingelheim International GmbH, Oracle Corporation, Thermo Fisher Scientific Inc., Albany Molecular Research Inc., ChemAxon Ltd., Amazon Web Services Inc., Schrödinger LLC., Core Informatics LLC, Informatics Matters Ltd., Tata Consultancy Services Limited, Novo Informatics Pvt. Ltd., IO Informatics Inc., GVK Biosciences Private Limited, Dassault Systèmes SE, Recursion Pharmaceuticals Inc., Cyclica Inc., Valence Discovery Inc., Valo Health Inc., Cognizant Technology Solutions Corporation, Wipro Limited, Mindtree Limited, Persistent Systems Limited, Mphasis Limited.

North America was the largest region in the drug discover informatics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the drug discovery informatics market during the forecast period. The regions covered in the drug discovery informatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery informatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Drug discovery informatics involves the development of systems designed to operate more efficiently with the vast volumes of clinical trial and treatment data. This field aims to facilitate the management of medical information, expediting the study and development of successful new treatments.

Key services in drug discovery informatics are categorized into in-house and outsourced solutions. In-house refers to computer programs, both in source and object code form, specifically tailored to the group's business needs and developed by the company itself rather than licensed from external sources. Various modalities, including cloud-based systems and in-campus applications, are employed for tasks such as data sequencing, molecular docking, identification and validation, as well as target data analysis. The end-users benefiting from these services encompass pharmaceutical companies, contract research organizations, and biotechnology companies.

The drug discovery informatics market research report is one of a series of new reports that provides drug discovery informatics market statistics, including drug discovery informatics industry global market size, regional shares, competitors with a drug discovery informatics market share, detailed drug discovery informatics market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery informatics industry. This drug discovery informatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug discovery informatics market consists of revenues earned by entities by providing literature databases, chemical databases, biological databases, predictive analytics, structures 2D and 3D, pharmacokinetic and pharmacodynamic data analysis, assay data analysis, genomics data analytics, and proteomics data analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug discovery informatics market also includes sales of CI-based (continuous integration) design tools and pharmacophore modelling tools, which are used in providing drug discovery informatics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.